0002004792-26-000001.txt : 20260731 0002004792-26-000001.hdr.sgml : 20260731 20260731081828 ACCESSION NUMBER: 0002004792-26-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260731 DATE AS OF CHANGE: 20260731 EFFECTIVENESS DATE: 20260731 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ratio Therapeutics, Inc. CENTRAL INDEX KEY: 0002004792 ORGANIZATION NAME: EIN: 863818343 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-592775 FILM NUMBER: 261225510 BUSINESS ADDRESS: STREET 1: ONE DESIGN CENTER PLACE STREET 2: SUITE 19-601 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 617-371-8898 MAIL ADDRESS: STREET 1: ONE DESIGN CENTER PLACE STREET 2: SUITE 19-601 CITY: BOSTON STATE: MA ZIP: 02210 D 1 primary_doc.xml X0708 D LIVE 0002004792 Ratio Therapeutics, Inc. ONE DESIGN CENTER PLACE SUITE 19-601 BOSTON MA MASSACHUSETTS 02210 617-371-8898 DELAWARE None None Corporation true John W. Hoppin One Design Center Place Suite 19-601 Boston MA MASSACHUSETTS 02210 Executive Officer Director John Babich One Design Center Place Suite 19-601 Boston MA MASSACHUSETTS 02210 Director Marc Becker One Design Center Place Suite 19-601 Boston MA MASSACHUSETTS 02210 Executive Officer Scott MacDonald One Design Center Place Suite 19-601 Boston MA MASSACHUSETTS 02210 Executive Officer William Cowan One Design Center Place Suite 19-601 Boston MA MASSACHUSETTS 02210 Director Susan Whoriskey One Design Center Place Suite 19-601 Boston MA MASSACHUSETTS 02210 Director Albert Holman One Design Center Place Suite 19-601 Boston MA MASSACHUSETTS 02210 Director Allan Green One Design Center Place Suite 19-601 Boston MA MASSACHUSETTS 02210 Director Brandon Ingersoll One Design Center Place Suite 19-601 Boston MA MASSACHUSETTS 02210 Director Pharmaceuticals Decline to Disclose 06b false 2026-07-16 false true false 0 69999974 69999974 0 false 57 0 0 0 false Ratio Therapeutics, Inc. /s/ John W. Hoppin John W. Hoppin Chief Executive Officer 2026-07-31